| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | Genomics to select treatment for patients with metastatic breast cancer |
| Creator | Andre et al. |
| Author | Thomas Filleron |
| Author | Maud Kamal |
| Author | Fernanda Mosele |
| Author | Monica Arnedos |
| Author | Florence Dalenc |
| Author | Marie-Paule Sablin |
| Author | Mario Campone |
| Author | Hervé Bonnefoi |
| Author | Claudia Lefeuvre-Plesse |
| Author | William Jacot |
| Author | Florence Coussy |
| Author | Jean-Marc Ferrero |
| Author | George Emile |
| Author | Marie-Ange Mouret-Reynier |
| Author | Nicolas Isambert |
| Author | Alice Mege |
| Author | Nawale Hajjaji |
| Author | Ludovic Lacroix |
| Author | Etienne Rouleau |
| Author | Alicia Tran-Dien |
| Author | Sandrine Boyault |
| Author | Valery Attignon |
| Author | Pierre Gestraud |
| Author | Nicolas Servant |
| Author | Christophe Le Tourneau |
| Author | Linda Larbi Cherif |
| Author | Isabelle Soubeyran |
| Author | Filippo Montemurro |
| Author | Alain Morel |
| Author | Amelie Lusque |
| Author | Marta Jimenez |
| Author | Alexandra Jacquet |
| Author | Thomas Bachelot |
| Abstract | Cancer progression is driven in part by genomic alterations1. The genomic characterization of cancers has shown interpatient heterogeneity regarding driver alterations2, leading to the concept that generation of genomic profiling in patients with cancer could allow the selection of effective therapies3,4. Although DNA sequencing has been implemented in practice, it remains unclear how to use its results. A total of 1,462?patients with HER2-non-overexpressing metastatic breast cancer were enroled to receive genomic profiling in the SAFIR02-BREAST trial. Two hundred and thirty-eight of these patients were randomized in two trials (nos. NCT02299999 and NCT03386162) comparing the efficacy of maintenance treatment5 with a targeted therapy matched to genomic alteration. Targeted therapies matched to genomics improves progression-free survival when genomic alterations are classified as level?I/II according to the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)6 (adjusted hazards ratio (HR): 0.41, 90% confidence interval (CI): 0.27-0.61, P? |
| Publication | Nature |
| Volume | 610 |
| Issue | 7931 |
| Pages | 343-348 |
| Date | 2022-10 |
| Journal Abbr | Nature |
| Language | eng |
| DOI | 10.1038/s41586-022-05068-3 |
| ISSN | 1476-4687 |
| Library Catalog | PubMed |
| Extra | PMID: 36071165 |
| Tags | Breast Neoplasms, clinic, Clinical Decision-Making, Disease Progression, DNA Mutational Analysis, Female, Genes, BRCA1, Genes, BRCA2, Genome, Human, Genomics, Humans, Neoplasm Metastasis, Phthalazines, Piperazines |
| Date Added | 2023/10/16 - 15:35:11 |
| Date Modified | 2023/10/16 - 17:44:08 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
